VCP
BNGO icon

Verus Capital Partners’s Bionano Genomics BNGO Stock Holding History

Verus Capital Partners’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-47
Closed -$17.1K – 312
2023
Q2 		$17.1K Hold
47
– – ﹤0.01% 295
2023
Q1 		$31.2K Buy
47
+3
+7% +$2.67K ﹤0.01% 289
2022
Q4 		$38.9K Sell
44
-3
-6% -$3.77K 0.01% 264
2022
Q3 		$51K Hold
47
– – 0.01% 269
2022
Q2 		$43K Buy
47
+1
+2% +$1.03K 0.01% 282
2022
Q1 		$43K Buy
+46
New +$62.1K 0.01% 325

Other funds holding BNGO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Verus Capital Partners's BNGO Position: Q3 2023 in Review

Verus Capital Partners sold out of Bionano Genomics (BNGO) in Q3 2023, closing a stake of 47 shares — an estimated $17.1K sold.

Verus Capital Partners first reported a position in BNGO in Q1 2022 and held it in 6 quarters. The position peaked at $51K in Q3 2022. 46 funds tracked by Wall St. Rank hold BNGO as of Q3 2023.

  • Verus Capital Partners reported no remaining Bionano Genomics position as of Q3 2023 after selling out during the quarter.
  • Verus Capital Partners sold 47 Bionano Genomics shares in Q3 2023, an estimated $17.1K.
  • Verus Capital Partners first reported a position in Bionano Genomics in Q1 2022 and held it in 6 quarters.
  • Verus Capital Partners's Bionano Genomics position peaked at $51K in Q3 2022.
  • 46 funds tracked by Wall St. Rank held Bionano Genomics as of Q3 2023.

Based on Verus Capital Partners's 13F filing for Q3 2023, filed 1 Nov 2023.